Latest / Morning Medical with Dr. Chow / Obesity Drugs Insights, Diabetes Trials, and Walking for Back Pain

Transcript

Obesity Drugs Insights, Diabetes Trials, and Walking for Back Pain · Morning Medical with Dr. Chow

• 0:00
  Hello and welcome to Morning Medical with Dr.
• 0:02
  Chow, where we bring you the latest medical and health news from around the world, using
• 0:07
  cutting-edge artificial intelligence.
• 0:10
  I'm your host, Dr.
• 0:12
  Chi-Ming Chow.
• 0:13
  I'm a family physician, general internist, and cardiologist based in Toronto, and I'm thrilled
• 0:18
  to have you with us today for episode 246.
• 0:22
  Let's dive into some fascinating developments in the world of medicine.
• 0:30
  Our first story today is about an experimental drug that's making waves in the field of weight
• 0:35
  management.
• 0:36
  Researchers have developed a medication called amycretin, which has shown promising results in
• 0:41
  early trials for weight loss.
• 0:43
  This new drug, developed by Novo Nordisk, is designed to mimic the effects of two hunger
• 0:49
  hormones: amylin and glucagon-like peptide 1, or GLP-1.
• 0:55
  These hormones play a crucial role in regulating appetite and creating a feeling of
• 1:00
  fullness.
• 1:02
  In a study involving 125 overweight or obese adults, participants who received weekly
• 1:08
  injections of amycretin lost significantly more weight compared to those who took a placebo.
• 1:15
  Those who received the highest doses, up to 60 milligrams, lost up to 24.3 percent of their
• 1:21
  body weight over 36 weeks, while the placebo group saw only a 1.1 percent reduction.
• 1:29
  This is quite a remarkable finding, indicating the potential effectiveness of amycretin in
• 1:34
  weight management.
• 1:36
  Interestingly, a previous phase 1 trial of an oral version of amycretin also demonstrated
• 1:42
  that the treatment was safe and tolerable, with a notable reduction in body weight compared to
• 1:47
  the placebo.
• 1:50
  Participants who took the pill version once a day experienced around a 10 percent weight
• 1:54
  loss, and those who doubled the dose saw a 13 percent reduction.
• 2:00
  Moreover, the study noted that participants did not hit a weight-loss plateau, suggesting that
• 2:05
  continued treatment might lead to further weight reduction.
• 2:09
  The results of these studies were presented at the American Diabetes Association meeting in
• 2:14
  Chicago and published in the medical journal, Lancet.
• 2:19
  Novo Nordisk is now preparing to move both the oral and injectable forms of amycretin into
• 2:25
  phase 3 trials for the management of obesity.
• 2:29
  While the results are promising, experts caution that side effects, similar to those
• 2:34
  seen with other GLP-1-based drugs, should be monitored carefully.
• 2:40
  These include gastrointestinal symptoms like nausea, vomiting, and decreased appetite.
• 2:46
  It's crucial to weigh these potential risks against the benefits, especially for long-term
• 2:50
  treatment.
• 2:52
  Experts, including Dr.
• 2:54
  Christine Ren-Fielding, director and chief of bariatric surgery at the New York University
• 2:59
  Langone Weight Management Program, emphasize that while pharmacological treatments like
• 3:04
  amycretin can play a significant role in managing obesity, they're most effective when
• 3:09
  combined with other interventions.
• 3:12
  Obesity is a complex, multifactorial disease that requires a comprehensive, long-term
• 3:17
  approach to management.
• 3:20
  As we await further developments from the upcoming phase 3 trials, it's important to keep
• 3:24
  in mind that while these medical advancements are exciting, they are not standalone solutions
• 3:29
  to complex health issues like obesity.
• 3:31
  It's about finding the right balance of treatments and lifestyle changes to achieve the
• 3:35
  best outcomes for patients.
• 3:39
  Our next story takes us to the realm of Type 1 diabetes and obesity, where a recent study has
• 3:45
  shed light on the potential benefits of a medication called semaglutide, commonly known
• 3:49
  as Ozempic.
• 3:51
  This drug, a GLP-1 receptor agonist, has been primarily used in the management of Type 2
• 3:57
  diabetes, but new research indicates it could also be beneficial for patients with Type 1
• 4:02
  diabetes who are struggling with obesity.
• 4:06
  In a 26-week, double-blind trial involving 72 adults, semaglutide showed promising results in
• 4:13
  reducing both glucose levels and body weight.
• 4:17
  The study was presented at the American Diabetes Association's annual meeting and
• 4:22
  simultaneously published in the New England Journal of Medicine Evidence.
• 4:27
  The participants, who had Type 1 diabetes for over a year, were required to have an HbA1c
• 4:33
  level between seven and ten percent, a body mass index of thirty or higher, and to be using
• 4:40
  an automated insulin delivery system for at least three months.
• 4:44
  The trial revealed that thirty-six percent of participants who received a weekly dose of one
• 4:49
  milligram of semaglutide achieved the primary composite outcome by week twenty-six.
• 4:55
  This outcome included spending more than seventy percent of the time in the target
• 4:58
  glucose range, less than four percent in hypoglycemia, and at least a five percent
• 5:03
  reduction in body weight.
• 5:05
  In contrast, none of the patients in the placebo group met these criteria.
• 5:11
  A significant secondary finding was the difference in HbA1c levels, with semaglutide
• 5:17
  users experiencing a 0.3 percentage point reduction compared to the placebo group.
• 5:24
  This underscores semaglutide's potential in improving glycemic control among these
• 5:30
  patients.
• 5:31
  Additionally, the semaglutide group spent more time in normoglycemic and target glycemic
• 5:37
  ranges, translating to better overall glucose management.
• 5:42
  Weight loss was another notable outcome, with participants on semaglutide losing an average
• 5:48
  of 19.4 pounds.
• 5:50
  This is particularly important as obesity is a considerable challenge in managing Type 1
• 5:55
  diabetes, often leading to insulin resistance and increased cardiovascular risk.
• 6:01
  While the study highlights these benefits, it also points out that semaglutide is not yet
• 6:06
  approved for Type 1 diabetes due to concerns about hypoglycemia and diabetic ketoacidosis.
• 6:13
  However, the trial did not report any cases of diabetic ketoacidosis, and severe hypoglycemia
• 6:19
  rates were low and comparable between both groups.
• 6:24
  Despite the encouraging outcomes, it's crucial to remember that semaglutide's use in this
• 6:29
  context is still off-label, and more research is needed to fully understand its safety and
• 6:35
  efficacy.
• 6:36
  Experts in the field, including Dr.
• 6:39
  Viral Shah from the Indiana University School of Medicine, emphasize the importance of
• 6:44
  conducting further clinical trials to explore the full potential of GLP-1 receptor agonists
• 6:50
  in managing Type 1 diabetes.
• 6:53
  In conclusion, while semaglutide shows promise in helping patients with Type 1 diabetes manage
• 6:59
  obesity and improve glycemic control, healthcare providers and patients should
• 7:04
  approach its use with caution, considering the need for more evidence to support its safety
• 7:09
  and effectiveness in this population.
• 7:13
  Today, we're going to explore a thought-provoking piece that challenges the
• 7:17
  traditional concept of what we consider "high risk" in medicine, particularly when it comes
• 7:22
  to sexual health.
• 7:24
  The article argues that the way we label certain behaviors as "high risk" is outdated
• 7:29
  and often stigmatizes individuals based on identity rather than actual behavior.
• 7:35
  In many electronic medical records, there's a checkbox for "high-risk sexual behavior." This
• 7:41
  checkbox is frequently ticked for men who have sex with men, regardless of their actual
• 7:46
  practices, such as condom use or taking pre-exposure prophylaxis, often known as PrEP.
• 7:53
  This approach ends up pathologizing identity rather than focusing on behavior, which can
• 7:58
  undermine trust and distort prevention strategies.
• 8:02
  The origins of these labels date back to the early days of the HIV/AIDS crisis when
• 8:09
  identifying groups by identity seemed necessary due to a lack of nuanced data.
• 8:16
  However, with modern advancements in data collection and understanding of risk,
• 8:22
  continuing to rely on these identity-based categories is both lazy and harmful.
• 8:28
  It's a form of medical profiling that disregards individual behavior and engagement
• 8:33
  with care.
• 8:35
  The article highlights doxycycline post-exposure prophylaxis, or DoxyPEP, as an
• 8:40
  example of how we can move beyond outdated framing.
• 8:44
  DoxyPEP is a medication shown to significantly reduce infections like syphilis and chlamydia
• 8:49
  when taken within seventy-two hours after unprotected sex.
• 8:54
  While the Centers for Disease Control and Prevention endorsed it following strong
• 8:59
  clinical trial results, its rollout has been met with some of the same anxieties that
• 9:04
  accompanied the introduction of PrEP, such as concerns over encouraging "risky" behavior.
• 9:10
  Ironically, a patient who is on PrEP, takes DoxyPEP consistently, and undergoes regular
• 9:16
  screening for sexually transmitted infections could be practicing "safer" sex than someone
• 9:23
  who relies solely on condoms.
• 9:27
  Yet, medicine tends to treat condoms as the gold standard, viewing anything else,
• 9:31
  particularly queer sex, as a deviation from it.
• 9:35
  The broader issue isn't the tools themselves but the framework we use to assess risk.
• 9:41
  The "high-risk sexual behavior" label was initially a way to flag patients for screening,
• 9:46
  but it has evolved into a shorthand for determining who deserves concern or caution,
• 9:52
  reinforcing a hierarchy where heterosexual, condom-using sex is seen as responsible, and
• 9:57
  everything else is not.
• 9:59
  These labels can serve insurers and bureaucratic systems by justifying coverage
• 10:04
  limitations, but they often lead to confusion, stigma, and mistrust for patients.
• 10:11
  They obstruct care rather than support it, especially for those navigating systems not
• 10:16
  designed with their needs in mind.
• 10:19
  The rise in sexually transmitted infections over the past decade, along with uneven uptake
• 10:25
  of prevention tools like PrEP and DoxyPEP, highlights the need for change.
• 10:30
  Patients should not feel discouraged from discussing their sexual health, and providers
• 10:35
  should not hesitate to offer these tools due to moral discomfort or fear of enabling risky
• 10:40
  behavior.
• 10:42
  In conclusion, risk is not an identity, and queer sex is not a problem to be solved.
• 10:49
  When patients are proactive and using the best prevention tools available, we should recognize
• 10:54
  them as informed rather than labeling them as dangerous.
• 10:59
  In our final story today, we're turning our attention to a simple yet effective activity
• 11:04
  that could potentially reduce the risk of lower back pain.
• 11:08
  Chronic lower back pain is a prevalent and costly condition affecting millions worldwide,
• 11:14
  and a new study from Norway suggests that taking longer walks could be a key to
• 11:18
  alleviating this issue.
• 11:20
  The research, published in the Journal of the American Medical Association Network Open,
• 11:26
  explored the effects of daily walking volume and intensity on the incidence of chronic lower
• 11:31
  back pain.
• 11:33
  The study involved more than eleven thousand participants over the age of twenty, who
• 11:37
  reported any occurrences of lower back pain lasting three months or longer over the past
• 11:42
  year.
• 11:43
  According to the study, participants who walked for more than one hundred minutes a day had a
• 11:48
  twenty-three percent lower risk of experiencing chronic lower back pain compared to those who
• 11:54
  walked less than seventy-eight minutes daily.
• 11:57
  Interestingly, while both walking volume and intensity were linked to a reduced risk of
• 12:02
  pain, the volume of walking had a more pronounced effect than the intensity.
• 12:08
  These findings highlight the potential benefits of walking as a simple, accessible form of
• 12:13
  physical activity that could be incorporated into public health strategies to mitigate the
• 12:17
  occurrence of chronic lower back pain.
• 12:20
  Dr.
• 12:21
  Arthur L.
• 12:22
  Jenkins the Third, a board-certified neurosurgeon and founder of Jenkins NeuroSpine
• 12:26
  in New York City, supports these findings, noting that he encourages his patients to walk
• 12:31
  regularly and engage their core muscles while doing so to maximize the benefits.
• 12:37
  Chronic lower back pain is a significant health issue, with statistics revealing that more than
• 12:43
  a quarter of Americans report suffering from it or related sciatic pain.
• 12:48
  Thus, promoting walking as a routine activity could offer a substantial public health
• 12:53
  benefit, potentially reducing healthcare costs and improving the quality of life for many
• 12:57
  individuals.
• 12:59
  As always, it's important to tailor physical activity to individual capabilities and consult
• 13:05
  healthcare professionals, especially if there are existing orthopedic concerns.
• 13:10
  However, this study reinforces the idea that simple lifestyle changes can have a meaningful
• 13:16
  impact on our health.
• 13:18
  That concludes today's episode of Morning Medical with Dr.
• 13:21
  Chow.
• 13:22
  Thank you for joining us, and I hope you found these stories as insightful as I did.
• 13:26
  Remember, staying informed and making small, positive changes can lead to better health
• 13:30
  outcomes.
• 13:31
  Until next time, take care and keep walking!